A new study by Washington University School of Medicine in St. Louis found that two anti-inflammatory drugs, abatacept and infliximab, reduced deaths among patients hospitalized with severe COVID-19.
The two drugs are typically used to treat inflammatory diseases such as rheumatoid arthritis and psoriasis. When tested in clinical trials, they reduced the likelihood of death when compared with standard care alone.